Co-Pay Relief Program Fund Notices
Would you like to be notified when any new funds open, or when any of our current funds re-open? If so, please sign up using the “Get Notified” link below. As a member of our subscriber community you will receive important news about all of our disease funds, so join today!
Approved and Donation Ready
This fund has been developed in response to patients who have contacted PAF for help with their medication expenses and could not find help. While this fund has been fully designed and we are ready to provide needed support to these patient communities, this fund is not yet able to accept applications for assistance as we are still working to secure charitable donations that will allow us to open it.
If you, or someone you know, would like to contribute to this fund, please visit our Donors page for more information on how to provide critical support for patients in need.Fund Type
Co-Pay, Co-insurance & Deductible (medications and office visits)Maximum Award Level
- Household Income Requirements 400% or less of Federal Poverty Guideline (FPG) (adjusted for Cost of Living Index (COLI) and number in household)
- Insurance Requirements All Insurance Types
- Must reside and receive treatment in the United States.
About Mucopolysaccharidosis VI
Mucopolysaccharidosis type 6 (MPS 6) is a lysosomal storage disease with progressive multisystem involvement, associated with a deficiency of arylsulfatase B (ASB) leading to the accumulation of dermatan sulfate. These materials remain stored in the body’s cells, causing progressive damage, causing many tissues and organs to enlarge, become inflamed or scarred, and eventually waste away. Skeletal abnormalities are also common in this condition. Mucopolysaccharidosis type 6MPS VI is estimated to occur in 1 in 250,000 to 600,000 newborns. This is a progressive condition that causes many tissues and organs to enlarge and become inflamed or scarred. Skeletal abnormalities are also common in this condition. People with MPS VI generally do not display any features of the condition at birth. They often begin to show signs and symptoms of MPS VI during early childhood. The features of MPS VI affect many bodily systems, including skeletal, cardiac, and respiratory. Skeletal abnormalities include a large head with a buildup of fluid in the brain, distinctive-looking facial features that are described as “coarse,” and a large tongue. Other skeletal features include short stature, joint deformities that affect mobility, and dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray. People with MPS VI may develop a narrowing of the spinal canal (spinal stenosis) in the neck, which can compress and damage the spinal cord. Cardiac problems in people with MPS VI typically includes heart valve abnormalities. Respiratory abnormalities in this condition may involve the airway becoming narrow, which leads to frequent upper respiratory infections and short pauses in breathing during sleep (sleep apnea). Other names for this condition include: Arylsulfatase B deficiency, Maroteaux-Lamy Syndrome, MPS VI, MPS6, Mucopolysaccharidosis VI, and Polydystrophic Dwarfism.
- Good Days877-968-7233
- Healthwell Foundation800-675-8416
- National Organization for Rare Disorders800-999-6673
- Needy Meds800-503-6897
- Patient Access Network Foundation866-316-7263
- Patient Services Inc.800-366-7741
- The Assistance Fund855-845-3663